Branchereau S, Ferry N, Myara A, Sato H, Kowai O, Trivin F, Houssin D, Danos O, Heard J
Laboratoire Rétrovirus et Transfert génétique, URA C.N.R.S. 1157, Institut Pasteur, Paris, France.
Chirurgie. 1993;119(10):642-8.
The in vivo procedure for retrovirus-mediated gene transfer into rat liver allows genetic modification of 1 to 5% hepatocytes and the expression of a foreign gene for more than one year. We have used the Gunn rat as a model of the human Crigler-Najjar type I syndrome to assess the pertinence of this approach for the treatment of severe liver genetic diseases. After transfer of the rat bilirubin uridin diphosphate-glucuronosyl transferase cDNA into hepatocytes, 15 Gunn rats were examined during several months and sacrificed. Bilirubin glucuronides were excreted in the bile of all recipients, and serum bilirubin levels were significantly reduced in the treated population. The decrease was more than 40% in 5 of the 15 rats. These date showed that long term expression of a therapeutic protein can be obtain after in vivo retrovirus-mediated gene transfer into the liver.
通过逆转录病毒介导将基因导入大鼠肝脏的体内实验方法,可使1%至5%的肝细胞实现基因修饰,并使外源基因表达超过一年。我们以冈恩大鼠作为人类Ⅰ型克里格勒 - 纳贾尔综合征的模型,来评估这种方法对治疗严重肝脏遗传性疾病的适用性。将大鼠胆红素尿苷二磷酸 - 葡萄糖醛酸基转移酶cDNA导入肝细胞后,对15只冈恩大鼠进行了数月观察,然后处死。所有接受治疗的大鼠胆汁中均排出了胆红素葡萄糖醛酸酯,且治疗组大鼠的血清胆红素水平显著降低。15只大鼠中有5只的胆红素水平下降超过40%。这些数据表明,通过体内逆转录病毒介导将基因导入肝脏后可实现治疗性蛋白质的长期表达。